Discrete effects of A57G-myosin essential light chain mutation associated with familial hypertrophic cardiomyopathy

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 305, Issue 4, 2013, Pages

  Kazmierczak, Katarzyna ^a   Paulino, Ellena C ^a   Huang, Wenrui ^a   Muthu, Priya ^a   Liang, Jingsheng ^a   Yuan, Chen Ching ^a   Rojas, Ana I ^a   Hare, Joshua M ^a   Szczesna Cordary, Danuta ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Ca2+ sensitivity of contraction; Echocardiography; Hypertrophic cardiomyopathy; Myosin essential light chain; Pressure volume loops

Indexed keywords

A57G MYOSIN ESSENTIAL LIGHT CHAIN; CALCIUM ION; MYOSIN ADENOSINE TRIPHOSPHATASE; MYOSIN LIGHT CHAIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISEASE COURSE; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; GENE EXPRESSION PROFILING; GENE MUTATION; HEART AFTERLOAD; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART PAPILLARY MUSCLE; HEART PERFORMANCE; HEART PRELOAD; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HISTOPATHOLOGY; HYPERTROPHIC CARDIOMYOPATHY; IN VITRO STUDY; IN VIVO STUDY; INFERIOR CAVA VEIN OBSTRUCTION; MOUSE; MUSCLE RELAXATION; MUSCLE RIGIDITY; MUSCLE STRETCHING; MUSCLE THICKNESS; MYOFILAMENT; NONHUMAN; PHENOTYPE; PHOTOLYSIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

CA2+ SENSITIVITY OF CONTRACTION; ECHOCARDIOGRAPHY; HYPERTROPHIC CARDIOMYOPATHY; MYOSIN ESSENTIAL LIGHT CHAIN; PRESSURE-VOLUME LOOPS;

ANIMALS; BIOMECHANICS; CALCIUM; CARDIOMYOPATHY, HYPERTROPHIC, FAMILIAL; DISEASE MODELS, ANIMAL; EXCITATION CONTRACTION COUPLING; FIBROSIS; GENETIC PREDISPOSITION TO DISEASE; HEMODYNAMICS; HUMANS; KINETICS; MICE; MICE, TRANSGENIC; MUTATION; MYOCARDIAL CONTRACTION; MYOFIBRILS; MYOSIN LIGHT CHAINS; PAPILLARY MUSCLES; PHENOTYPE; PHOSPHORYLATION; SWINE; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84881621612     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00107.2013     Document Type: Article

References (56)

1. Abraham TP, Jones M, Kazmierczak K, Liang HY, Pinheiro AC, Wagg CS, Lopaschuk GD, Szczesna-Cordary D. Diastolic dysfunction in familial hypertrophic cardiomyopathy transgenic model mice. Cardiovasc Res 82: 84-92, 2009.
2. Alcalai R, Seidman JG, Seidman CE. Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics. J Cardiovasc Electrophysiol 19: 104-110, 2008.
3. Andersen PS, Hedley PL, Page SP, Syrris P, Moolman-Smook JC, McKenna WJ, Elliott PM, Christiansen M. A novel Myosin essential light chain mutation causes hypertrophic cardiomyopathy with late onset and low expressivity. Biochem Res Int 2012: 685108, 2012.
4. 2+ sensitization causes susceptibility to cardiac arrhythmia in mice. J Clin Invest 118: 3893-3903, 2008.
5. Borejdo J, Szczesna-Cordary D, Muthu P, Metticolla P, Luchowski R, Gryczynski Z, Gryczynski I. Single molecule detection approach to muscle study: kinetics of a single cross-bridge during contraction of muscle. Methods Mol Biol 875: 311-334, 2012.
6. Borlaug BA, Kass DA. Ventricular-vascular interaction in heart failure. Heart Fail Clin 4: 23-36, 2008.
7. Deacon JC, Bloemink MJ, Rezavandi H, Geeves MA, Leinwand LA. Erratum to: Identification of functional differences between recombinant human alpha and beta cardiac myosin motors. Cell Mol Life Sci 69: 4239-4255, 2012.
8. Dweck D, Reyes-Alfonso A Jr, Potter JD. Expanding the range of free calcium regulation in biological solutions. Anal Biochem 347: 303-315, 2005.
9. Fiske CH, Subbarow Y. The colorimetric determination of phosphorus. J Biol Chem 66: 375-400, 1925.
10. Fitzsimons DP, Patel JR, Moss RL. Role of myosin heavy chain composition in kinetics of force development and relaxation in rat myocardium. J Physiol 513: 171-183, 1998.
11. Force T, Bonow RO, Houser SR, Solaro RJ, Hershberger RE, Adhikari B, Anderson ME, Boineau R, Byrne BJ, Cappola TP, Kalluri R, LeWinter MM, Maron MS, Molkentin JD, Ommen SR, Regnier M, Tang WH, Tian R, Konstam MA, Maron BJ, Seidman CE. Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute. Circulation 122: 1130-1133, 2010.
12. Frey N, Luedde M, Katus HA. Mechanisms of disease: hypertrophic cardiomyopathy. Nat Rev Cardiol 9: 91-100, 2012.
13. Garcia-Pavia P, Vazquez ME, Segovia J, Salas C, Avellana P, Gomez-Bueno M, Vilches C, Gallardo ME, Garesse R, Molano J, Bornstein B, Alonso-Pulpon L. Genetic basis of end-stage hypertrophic cardiomyopathy. Eur J Heart Fail 13: 1193-1201, 2011.
14. Geeves MA. Molecular motors: stretching the lever-arm theory. Nature 415: 129-131, 2002.
15. Geeves MA, Holmes KC. The molecular mechanism of muscle contraction. Adv Protein Chem 71: 161-193, 2005.
16. Hanson KR, Ling R, Havir E. A computer program for fitting data to the Michaelis-Menten equation. Biochem Biophys Res Commun 29: 194-197, 1967.
17. Hernandez OM, Jones M, Guzman G, Szczesna-Cordary D. Myosin essential light chain in health and disease. Am J Physiol Heart Circ Physiol 292: H1643-H1654, 2007.
18. Hill TL, Einsenberg E, Greene LE. Theoretical model for the cooperative equilibrium binding of myosin subfragment-1 to the actin-troponintropomyosin complex. Proc Natl Acad Sci USA 77: 3186-3190, 1980.
19. Janssen PM. Kinetics of cardiac muscle contraction and relaxation are linked and determined by properties of the cardiac sarcomere. Am J Physiol Heart Circ Physiol 299: H1092-H1099, 2010.
20. Janssen PM. Myocardial contraction-relaxation coupling. Am J Physiol Heart Circ Physiol 299: H1741-H1749, 2010.
21. Johns EC, Ryder KO, Hodson EA, Hart G, Mulligan IP, Lipscomb S, Ashley CC. Investigating the relaxation rate, following diazo-2 photolysis, of a skinned trabecular preparation from guinea-pig hypertrophied left ventricle. Pflügers Arch 438: 771-777, 1999.
22. Kaski JP, Syrris P, Esteban MT, Jenkins S, Pantazis A, Deanfield JE, McKenna WJ, Elliott PM. Prevalence of sarcomere protein gene mutations in preadolescent children with hypertrophic cardiomyopathy. Circ Cardiovasc Genet 2: 436-441, 2009.
23. Kazmierczak K, Muthu P, Huang W, Jones M, Wang Y, Szczesna-Cordary D. Myosin regulatory light chain mutation found in hypertrophic cardiomyopathy patients increases isometric force production in transgenic mice. Biochem J 442: 95-103, 2012.
24. Kazmierczak K, Xu Y, Jones M, Guzman G, Hernandez OM, Kerrick WG, Szczesna-Cordary D. The role of the N-terminus of the myosin essential light chain in cardiac muscle contraction. J Mol Biol 387: 706-725, 2009.
25. Keren A, Syrris P, McKenna WJ. Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression. Nat Clin Pract Cardiovasc Med 5: 158-168, 2008.
26. Kerrick WG, Kazmierczak K, Xu Y, Wang Y, Szczesna-Cordary D. Malignant familial hypertrophic cardiomyopathy D166V mutation in the ventricular myosin regulatory light chain causes profound effects in skinned and intact papillary muscle fibers from transgenic mice. FASEB J 23: 855-865, 2009.
27. Knollmann BC, Roden DM. A genetic framework for improving arrhythmia therapy. Nature 451: 929-936, 2008.
28. Lan F, Lee AS, Liang P, Sanchez-Freire V, Nguyen PK, Wang L, Han L, Yen M, Wang Y, Sun N, Abilez OJ, Hu S, Ebert AD, Navarrete EG, Simmons CS, Wheeler M, Pruitt B, Lewis R, Yamaguchi Y, Ashley EA, Bers DM, Robbins RC, Longaker MT, Wu JC. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 12: 101-113, 2013.
29. Lee W, Hwang TH, Kimura A, Park SW, Satoh M, Nishi H, Harada H, Toyama J, Park JE. Different expressivity of a ventricular essential myosin light chain gene Ala57Gly mutation in familial hypertrophic cardiomyopathy. Am Heart J 141: 184-189, 2001.
30. Lopez JE, Myagmar BE, Swigart PM, Montgomery MD, Haynam S, Bigos M, Rodrigo MC, Simpson PC. Beta-myosin heavy chain is induced by pressure overload in a minor subpopulation of smaller mouse cardiac myocytes. Circ Res 109: 629-638, 2011.
31. Lu X, Kazmierczak K, Jiang X, Jones M, Watt J, Helfman DM, Moore JR, Szczesna-Cordary D, Lossos IS. Germinal center-specific protein human germinal center associated lymphoma directly interacts with both myosin and actin and increases the binding of myosin to actin. FEBS J 278: 1922-1931, 2011.
32. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 287: 1308-1320, 2002.
33. Maron BJ. The young competitive athlete with cardiovascular abnormalities: causes of sudden death, detection by preparticipation screening, and standards for disqualification. Card Electrophysiol Rev 6: 100-103, 2002.
34. McKillop DF, Geeves MA. Regulation of the interaction between actin and myosin subfragment 1: evidence for three states of the thin filament. Biophys J 65: 693-701, 1993.
35. Mettikolla P, Calander N, Luchowski R, Gryczynski I, Gryczynski Z, Zhao J, Szczesna-Cordary D, Borejdo J. Cross-bridge kinetics in myofibrils containing familial hypertrophic cardiomyopathy R58Q mutation in the regulatory light chain of myosin. J Theor Biol 284: 71-81, 2011.
36. 2+ sensitivity and cross-bridge detachment kinetics. Am J Physiol Heart Circ Physiol 304: H253-H259, 2013.
37. Morita H, Rehm HL, Menesses A, McDonough B, Roberts AE, Kucherlapati R, Towbin JA, Seidman JG, Seidman CE. Shared genetic causes of cardiac hypertrophy in children and adults. N Engl J Med 358: 1899-1908, 2008.
38. Muthu P, Kazmierczak K, Jones M, Szczesna-Cordary D. The effect of myosin RLC phosphorylation in normal and cardiomyopathic mouse hearts. J Cell Mol Med 16: 911-919, 2012.
39. Muthu P, Mettikolla P, Calander N, Luchowski R, Gryczynski I, Gryczynski Z, Szczesna-Cordary D, Borejdo J. Single molecule kinetics in the familial hypertrophic cardiomyopathy D166V mutant mouse heart. J Mol Cell Cardiol 48: 989-998, 2010.
40. Muthu P, Wang L, Yuan CC, Kazmierczak K, Huang W, Hernandez OM, Kawai M, Irving TC, Szczesna-Cordary D. Structural and functional aspects of the myosin essential light chain in cardiac muscle contraction. FASEB J 25: 4394-4405, 2011.
41. Olson TM, Karst ML, Whitby FG, Driscoll DJ. Myosin light chain mutation causes autosomal recessive cardiomyopathy with mid-cavitary hypertrophy and restrictive physiology. Circulation 105: 2337-2340, 2002.
42. Page SP, Kounas S, Syrris P, Christiansen M, Frank-Hansen R, Andersen PS, Elliott PM, McKenna WJ. Cardiac myosin binding protein-C mutations in families with hypertrophic cardiomyopathy: disease expression in relation to age, gender, and long term outcome. Circ Cardiovasc Genet 5: 156-166, 2012.
43. Poetter K, Jiang H, Hassanzadeh S, Master SR, Chang A, Dalakas MC, Rayment I, Sellers JR, Fananapazir L, Epstein ND. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet 13: 63-69, 1996.
44. Rayment I, Rypniewski WR, Schmidt-Base K, Smith R, Tomchick DR, Benning MM, Winkelmann DA, Wesenberg G, Holden HM. Three-dimensional structure of myosin subfragment-1: a molecular motor. Science 261: 50-58, 1993.
45. Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C, Benaiche A, Isnard R, Dubourg O, Burban M, Gueffet JP, Millaire A, Desnos M, Schwartz K, Hainque B, Komajda M; EUROGENE Heart Failure Project. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 107: 2227-2232, 2003.
46. Schober T, Huke S, Venkataraman R, Gryshchenko O, Kryshtal D, Hwang HS, Baudenbacher FJ, Knollmann BC. Myofilament Ca sensitization increases cytosolic Ca binding affinity, alters intracellular Ca homeostasis, and causes pause-dependent Ca-triggered arrhythmia. Circ Res 111: 170-179, 2012.
47. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 342: 1778-1785, 2000.
48. Szczesna-Cordary D, Guzman G, Zhao J, Hernandez O, Wei J, Diaz-Perez Z. The E22K mutation of myosin RLC that causes familial hypertrophic cardiomyopathy increases calcium sensitivity of force and ATPase in transgenic mice. J Cell Sci 118: 3675-3683, 2005.
49. Szczesna-Cordary D, Jones M, Moore JR, Watt J, Kerrick WGL, Xu Y, Wang Y, Wagg C, Lopaschuk GD. Myosin regulatory light chain E22K mutation results in decreased cardiac intracellular calcium and force transients. FASEB J 21: 3974-3985, 2007.
50. Tardiff JC, Hewett TE, Factor SM, Vikstrom KL, Robbins J, Leinwand LA. Expression of the beta (slow)-isoform of MHC in the adult mouse heart causes dominant-negative functional effects. Am J Physiol Heart Circ Physiol 278: H412-H419, 2000.
51. Trybus KM. Biochemical studies of myosin. Methods 22: 327-335, 2000.
52. Trybus KM. Role of myosin light chains. J Muscle Res Cell Motil 15: 587-594, 1994.
53. Ueta CB, Oskouei BN, Olivares EL, Pinto JR, Correa MM, Simovic G, Simonides WS, Hare JM, Bianco AC. Absence of myocardial thyroid hormone inactivating deiodinase results in restrictive cardiomyopathy in mice. Mol Endocrinol 26: 809-818, 2012.
54. Wang L, Muthu P, Szczesna-Cordary D, Kawai M. Characterizations of myosin essential light chain's N-terminal truncation mutant Delta43 in transgenic mouse papillary muscles by using tension transients in response to sinusoidal length alterations. J Muscle Res Cell Motil 34: 93-105, 2013.
55. 2+ and force transients in myosin RLC transgenic mouse fibers expressing malignant and benign FHC mutations. J Mol Biol 361: 286-299, 2006.
56. Warren CM, Greaser ML. Method for cardiac myosin heavy chain separation by sodium dodecyl sulfate gel electrophoresis. Anal Biochem 320: 149-151, 2003.